Pragnesh Patel, MD
Allergy & Immunology · Altamonte Springs, FLNPI 1912973033
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Pharming Healthcare, Inc. accounts for 62.2% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $18,132 and has fallen 58.7% since, to $7,485 in 2025. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 860 payments — averaging $98.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$52K
- CSL Behring$5K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- AstraZeneca$4K
- Shire North American Group Inc$4K
- Biocryst US Sales Co., LLC$3K
- plus $11K from 35 others
What the payments were for
- Consulting fees$25,58630%
- Speaking & faculty fees$38,84046%
- Travel & lodging$1,6772%
- Food & beverage$18,10821%
- Education$1440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,354 in reported general payments places this provider in the 90th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $654,571 |
| IcatibantIcatibant Acetate | 16 | $139,666 |
| XolairOmalizumab | 45 | $121,558 |
| Dupixent SyringeDupilumab | 28 | $103,475 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $93,562 |
| Dupixent PenDupilumab | 13 | $50,206 |
| TezspireTezepelumab-Ekko | 12 | $46,139 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $30,040 |
| Spiriva RespimatTiotropium Bromide | 34 | $19,427 |
| Arnuity ElliptaFluticasone Furoate | 35 | $11,402 |
| DuleraMometasone/Formoterol | 20 | $10,617 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $9,633 |
| Epinephrine | 27 | $5,744 |
| BreynaBudesonide/Formoterol Fumarate | 24 | $4,665 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $4,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $5,033 | $654,57113 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,078 | $135,004218 claims |
| AstraZenecaTezspire, Symbicort | $3,561 | $55,77139 claims |
| Boehringer IngelheimSpiriva Respimat | $67 | $19,42734 claims |
| MerckDulera | $13 | $10,61720 claims |
| Hikma Pharmaceuticals USAEpinephrine | $16 | $5,74427 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $1,791 | $3,75212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Altamonte Springs
- Andrew BaggAltamonte Springs$113K
- Warit JithpratuckAltamonte Springs$24K
- Jose Arias JrAltamonte Springs$14K
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.